Statin-associated myopathies are frequently encountered or at least considered in patients being treated for elevated cholesterol. Outlining a rationale approach to such patients and understanding newer concepts in the myopathies associated with statins is important for the rheumatologist. Assessing disease activity in myositis and its extramuscular manifestations, e.g. lung disease, is a challenge and it is important for the rheumatologist to understand potential biomarkers to longitudinally follow patients with myositis. Similarly, the cutaneous features of dermatomyositis are protean in nature and sometimes difficult to treat, but may provide prognostic clues.
Upon completion of this session, participants should be able to:
- to identify and discuss recent advances in statin-associated myopathy and to determine the appropriate workup for a patient with statin myopathy
- to identify emerging biomarkers in myositis and to understand the rationale of their importance
- to recognize the phenotypic features of dermatomyositis and their prognostic and therapeutic implications
|Moderators:||Rohit Aggarwal, MD, University of Pittsburgh Medical Center and Chester V. Oddis, MD, University of Pittsburgh|
To see other sessions for this day, use the date buttons to the left.